Compare Cassava Sciences Inc (FLNA) vs NatWest Group plc American Depositary Shares (each representing two (2) Ordinary Shares) (NWG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cassava Sciences Inc vs NatWest Group plc American Depositary Shares (each representing two (2) Ordinary Shares) — how do they compare? Cassava Sciences Inc trades at $0.83 (market cap $39.40M), while NatWest Group plc American Depositary Shares (each representing two (2) Ordinary Shares) trades at $17.05 (market cap $66.98B). The key difference: NatWest Group plc American Depositary Shares (each representing two (2) Ordinary Shares) is far larger — about 1700× Cassava Sciences Inc's market cap, and NatWest Group plc American Depositary Shares (each representing two (2) Ordinary Shares) pays a 5.5% dividend while Cassava Sciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Cassava Sciences Inc for 37 Days and NatWest Group plc American Depositary Shares (each representing two (2) Ordinary Shares) for 0 Days on average.
| FLNA | NWG | |
|---|---|---|
Market Cap | $39.40M | $66.98B |
Volume | 759,018 | 5,259,060 |
Sector | Health | Financials |
52-Week High | $4.64 | $19.42 |
52-Week Low | $0.68 | $13.89 |
Typical Hold Time | 37 Days | 0 Days |
Enterprise Value | -$43.28M | $140.55B |
Dividend Yield | — | 5.5% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Filana Therapeutics (FLNA) trades at $0.82, down 6.77% today, amid bearish technical signals but with positive fundamental catalysts. The company shows improving quarterly EPS beats and a favorable EV/EBITDA of 1.03, though it remains unprofitable with negative cash flow. Recent FDA clearance for its epilepsy drug trial has generated optimism, reflected in strong analyst buy ratings (67% consensus).
The outlook balances clinical progress against financial strain. The FDA hold lift on simufilam provides a clear near-term catalyst for Phase 2a trials starting in 2027, supporting the bullish analyst view. However, high cash burn (-$33M net CF in 2025) and lack of revenue pose significant risks to sustainability, requiring careful monitoring of funding and trial milestones.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →About NatWest Group plc American Depositary Shares (each representing two (2) Ordinary Shares)
NatWest Group is a UK banking company serving personal, business, and institutional customers. Its services include deposits, lending, payments, and wealth management.
Read more on NWG →
